Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRWD5769 + cemiplimab in advanced solid malignancies
ACTRN12623001077651Phase 2Active, not recruiting
- Sponsor
- Grey Wolf Therapeutics
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of GRWD5769 and cemiplimab in Non-hematologic malignancy, Cervical Cancer (CC), hepatocellular carcinoma (HCC) and 6 more (6 arms), sponsored by Grey Wolf Therapeutics. Primary endpoints: Incidence, type, and severity of adverse events, Dose-limiting toxicities and 1 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
GRWD5769cemiplimab
03
Conditions
Non-hematologic malignancyCervical Cancer (CC)hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ACTRN12623001077651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001077651.